Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares MSCI Germany (DAX) (EWG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares MSCI Germany (DAX) — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while iShares MSCI Germany (DAX) trades at $41.27. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals.
| ACAD | EWG | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $44.56 |
52-Week Low | $20.06 | $38.08 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EWG is trading at $42.66, up 0.83% with a bullish technical signal from moving averages. The stock shows strong momentum indicators but RSI suggests potential overbought conditions. Recent European market strength and German economic reforms provide positive backdrop. Dividend of $0.83 scheduled for June 2026 indicates shareholder returns commitment.
Outlook remains positive with European equity momentum and potential short-squeeze dynamics. Key risks include ECB rate hikes impacting growth sectors and German industrial employment concerns. Investment opportunity lies in European market rotation and cyclical sector strength, though valuation metrics require monitoring given limited fundamental data availability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →
